Nanobiotix (NBTX) News Today → Guard Against the Coming Financial Upheaval (From Porter & Company) (Ad) Free NBTX Stock Alerts $7.29 +0.44 (+6.42%) (As of 10:58 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 30, 2024 | marketbeat.comNanobiotix's (NBTX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating on shares of Nanobiotix in a research report on Friday.April 29, 2024 | seekingalpha.comNanobiotix S.A. (NBTX) Q4 2023 Earnings Call TranscriptApril 26, 2024 | benzinga.comNanobiotix Stock (NASDAQ:NBTX), Earnings Estimates, EPS, and RevenueApril 24, 2024 | globenewswire.comNANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial ResultsApril 17, 2024 | globenewswire.comNANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024April 11, 2024 | marketbeat.comBaillie Gifford & Co. Has $20.89 Million Stock Holdings in Nanobiotix S.A. (NASDAQ:NBTX)Baillie Gifford & Co. increased its position in Nanobiotix S.A. (NASDAQ:NBTX - Free Report) by 48.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,869,030 shares of the company's stock after buying an aApril 3, 2024 | marketbeat.comNanobiotix (NASDAQ:NBTX) Trading Down 1.6%Nanobiotix (NASDAQ:NBTX) Trading Down 1.6%April 2, 2024 | globenewswire.comNanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-IrradiationMarch 6, 2024 | globenewswire.comNanobiotix to Present at Upcoming Investor Conferences in MarchFebruary 17, 2024 | marketbeat.comNanobiotix S.A. (NASDAQ:NBTX) Shares Bought by Baillie Gifford & Co.Baillie Gifford & Co. raised its holdings in Nanobiotix S.A. (NASDAQ:NBTX - Free Report) by 38.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,936,195 shares of the company's stock after purchaFebruary 12, 2024 | marketbeat.comJohnson & Johnson Buys Shares of 959,637 Nanobiotix S.A. (NASDAQ:NBTX)Johnson & Johnson bought a new stake in Nanobiotix S.A. (NASDAQ:NBTX - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 959,637 shares of the company's stock, valued at approximately $8,397,000.February 3, 2024 | marketbeat.comNanobiotix (NASDAQ:NBTX) Shares Down 2.3% Nanobiotix (NASDAQ:NBTX) Stock Price Down 2.3%January 31, 2024 | finance.yahoo.comNanobiotix to Present at the Guggenheim 6th Annual Biotechnology ConferenceJanuary 30, 2024 | finanznachrichten.deNanobiotix S.A.: Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer StudyJanuary 29, 2024 | finance.yahoo.comNanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer StudyJanuary 18, 2024 | seekingalpha.comNBTX Nanobiotix S.A.January 12, 2024 | marketbeat.comNanobiotix S.A. (NASDAQ:NBTX) Sees Large Increase in Short InterestNanobiotix S.A. (NASDAQ:NBTX - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 35,700 shares, an increase of 113.8% from the December 15th total of 16,700 shares. Based on an average trading volume of 19,000 shares, the days-to-cover ratio is currently 1.9 days.December 8, 2023 | realmoney.thestreet.comNanobiotix initiated with an Outperform at LeerinkDecember 4, 2023 | finance.yahoo.comNanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.November 15, 2023 | finanznachrichten.deNanobiotix S.A.: NANOBIOTIX Provides Third Quarter 2023 Operational and Financial UpdateNovember 13, 2023 | finance.yahoo.comNANOBIOTIX Provides Third Quarter 2023 Operational and Financial UpdateNovember 9, 2023 | finance.yahoo.comNANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023November 9, 2023 | finanznachrichten.deNanobiotix S.A.: Voting Rights and Shares Capital of the CompanyNovember 7, 2023 | finance.yahoo.comNANOBIOTIX Announces Closing of Global OfferingNovember 6, 2023 | finance.yahoo.comNANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6MNovember 2, 2023 | msn.comWhy Nanobiotix (NBTX) Stock Is Plunging ThursdayNovember 2, 2023 | finance.yahoo.comNANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55MNovember 2, 2023 | morningstar.comNanobiotix SA ADR NBTXNovember 1, 2023 | finance.yahoo.comNANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash CovenantOctober 23, 2023 | finance.yahoo.comNANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023October 5, 2023 | msn.comNanobiotix falls after Phase 1 data for lead asset in head and neck cancerOctober 5, 2023 | markets.businessinsider.comUBS Reaffirms Their Buy Rating on Nanobiotix (NBTX)October 4, 2023 | finance.yahoo.comNanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 MonthsSeptember 29, 2023 | finance.yahoo.comNANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation OncologySeptember 28, 2023 | finance.yahoo.comNANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic CancerSeptember 27, 2023 | finanznachrichten.deNanobiotix S.A.: NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023September 26, 2023 | finance.yahoo.comNANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023September 19, 2023 | finance.yahoo.comNanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023September 5, 2023 | finance.yahoo.comNANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical OfficerAugust 31, 2023 | finance.yahoo.comNANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 25, 2023 | seekingalpha.comNanobiotix: At A Crucial Juncture For DataAugust 15, 2023 | finance.yahoo.comNANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3August 4, 2023 | finance.yahoo.comNANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023July 20, 2023 | marketwatch.comNanobiotix Shares Rise 9% After Phase 1/2 Study for NBTXR3 BeginsJuly 19, 2023 | finance.yahoo.comNANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced CancersJuly 11, 2023 | msn.comNBTX Soars On Teaming Up with Janssen for NBTXR3July 10, 2023 | benzinga.comWhy Nanobiotix Stock Is Soaring MondayJuly 10, 2023 | msn.comBiggest stock movers today: Icahn Enterprises, Nanobiotix and moreJuly 10, 2023 | markets.businessinsider.comNanobiotix In License Deal With Johnson & Johnson Unit; Stock Climbs In Pre MarketJuly 10, 2023 | marketwatch.comNanobiotix Shares Soar on Licensing Deal With J&J Unit >NBTX Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address How to Make 100X on the AI Boom (Ad)For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market. Click for his six specific AI stock in the crosshairs NBTX Media Mentions By Week NBTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBTX News Sentiment▼1.890.57▲Average Medical News Sentiment NBTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBTX Articles This Week▼11▲NBTX Articles Average Week Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ESSA Pharma News Today FibroBiologics News Today Aquestive Therapeutics News Today Procaps Group News Today Akebia Therapeutics News Today Verastem News Today UroGen Pharma News Today XOMA News Today Vanda Pharmaceuticals News Today Neoleukin Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBTX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityWhat’s Really Next for America…Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
